Key result
The highest quartile of plasma thrombomodulin was associated with a lower risk of death and major disability at 3 months after ischemic stroke (OR/HR 0.75; 95% CI 0.59-0.97; ptrend=0.029).
Why the study?
Thrombomodulin has been implicated in ischemic stroke due to anticoagulant, anti-inflammatory, and cytoprotective properties, but its association with post-stroke clinical outcomes required investigation.
Do higher plasma thrombomodulin levels improve clinical outcomes in patients with acute ischemic stroke?
Population
3,532 Chinese ischemic stroke patients
Comparison
Higher vs lower quartiles of baseline plasma thrombomodulin levels
Design
Multicenter prognostic cohort study
Follow-up
3 months
Authors
Loading...
Does not support changing practice; leaves open whether thrombomodulin is a modifiable target in ischemic stroke.
Cohort (n=3,532)
Yes
Do higher plasma thrombomodulin levels improve clinical outcomes in patients with acute ischemic stroke?
Odds Ratio: 0.75 (95% CI 0.59–0.97)
p-value: p=0.029
Higher baseline plasma thrombomodulin levels are associated with a decreased risk of death and major disability at 3 months after ischemic stroke, suggesting a potential protective role.
Zhu et al. (2022) conducted a cohort in Ischemic stroke (n=3,532). Plasma thrombomodulin levels vs. Lower quartiles of plasma thrombomodulin was evaluated on Composite outcome of death and major disability (modified Rankin Scale [mRS] score ≥3) at 3 months after ischemic stroke (OR/HR 0.75, 95% CI 0.59-0.97, p=0.029). The highest quartile of plasma thrombomodulin was associated with a lower risk of death and major disability at 3 months after ischemic stroke (OR/HR 0.75; 95% CI 0.59-0.97; ptrend=0.029).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: